Compare Crispr Therapeutics AG (CRSP) vs Fidelity National Information Servcs Inc (FIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Fidelity National Information Servcs Inc — how do they compare? Crispr Therapeutics AG trades at $53.42 (market cap $4.88B), while Fidelity National Information Servcs Inc trades at $34.08 (market cap $17.71B). The key difference: Fidelity National Information Servcs Inc is far larger — about 3.6× Crispr Therapeutics AG's market cap, and Fidelity National Information Servcs Inc pays a 5.13% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Fidelity National Information Servcs Inc for 88 Days on average.
| CRSP | FIS | |
|---|---|---|
Market Cap | $4.88B | $17.71B |
Volume | 2,861,747 | 9,047,825 |
Sector | Health | Technology |
52-Week High | $74.92 | $68.57 |
52-Week Low | $44.34 | $32.44 |
Typical Hold Time | 77 Days | 88 Days |
Enterprise Value | $3.30B | $38.22B |
Dividend Yield | — | 5.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
FIS trades at $34.04, up 0.65% on the day, with a bearish technical signal from moving averages and oscillators. The company's valuation metrics appear attractive with a P/E of 5.27 and P/S of 1.46, while recent earnings have shown beats in Q1 and Q2 2026. Revenue is projected to grow to $12.2B in 2026, with net income margin improving to 27.64%. Recent news highlights contract wins and platform modernizations, supporting growth momentum.
The outlook for FIS is cautiously optimistic, with strong analyst support (56.76% buy ratings) and a consensus price target of $47.15 implying significant upside. However, risks include a high debt-to-asset ratio of 39.06% in 2025 and volatile cash flow trends. Investors should weigh the low valuation against execution risks and macroeconomic pressures in the financial technology sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Fidelity National Information Servcs Inc
Fidelity National Information Services' legacy operations provide core and payment processing services to banks, but its business has expanded over time. By acquiring Sungard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS now provides payment processing services for merchants and holds leading positions in the United States and United Kingdom. About a fourth of revenue is generated outside North America.
Read more on FIS →
